Advanced search
Start date

Construction and characterization of anti-FGF-2 scFv from 3F12E7 hybridoma

Grant number: 12/10623-2
Support type:Regular Research Grants
Duration: September 01, 2012 - February 28, 2015
Field of knowledge:Biological Sciences - Morphology
Principal Investigator:Jane Zveiter de Moraes
Grantee:Jane Zveiter de Moraes
Home Institution: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brazil
Assoc. researchers:Graciela Conceicao Pignatari ; Sang Won Han


Melanoma is a potentially fatal disorder and new options for treatment have been studied. Among them, those that aim to prevent growth of blood vessels that nourish the tumor. Associated with conventional cytotoxic therapies, the anti-angiogenic therapy has already shown its potential and its use was approved for the treatment of some tumors. Among the anti-angiogenic drugs are monoclonal antibodies (MAb) against angiogenic factors. A work being completed, developed by our group (FAPESP process 09/18631-1), shows the MAb against fibroblast growth factor -2 (FGF-2) 3F12E7 successfully inhibiting tumor growth and metastatic melanoma formation. MAb 3F12E7 was produced by immunization with human FGF-2 gene. To continue the project, we propose the construction of a single chain variable fragment scFv (single chain variable fragment) using the hybridoma 3F12E7. The antibodies in the form of scFv are constructed by genetic engineering. Being smaller, the scFv easily infiltrates into solid tumor masses. Besides this advantage over the whole antibody, the scFv, when injected into humans, do not cause immune response against the isotypic and allotypic markers, present in the constant regions of the immunoglobulin chains, which allow its injection for unlimited times. In this project, we propose the construction and characterization of the anti-FGF-2 scFv 3F12E7 for further evaluation of its efficiency in cellular and gene therapy. (AU)